Procarbazine, Lomustine and Vincristine Toxicity in Low-Grade Gliomas

Abstract

Background Procarbazine, lomustine, and vincristine (pcv) significantly improve survival outcomes in lgg (low-

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review

“…The results of our study are in line with the previous literature regarding the hematological toxicity of PCV [11]. Grade 3 hematological toxicity was observed in more than one-third of our randomly selected patients.…”

“…Scientific literature shows that the renal function of 10% of patients is impacted by PCV [11]. Our study shows that 1.6 % of patients had elevated levels of creatinine which can cause the reduction of Procarbazine/ Lomustine.…”

“…One-third of patients had delayed treatment due to treatmentrelated toxicities. Modification of the dosage in the face of hepatic or renal dysfunction is probably advisable [9][10][11][12][13][14][15].…”

Successful oral desensitization and reintroduction in selected glioma patients with procarbazine‐mediated hypersensitivity

“…Survival can be prolonged with neurosurgery and adjuvant chemoradiotherapy, including the PCV regimen consisting of procarbazine, lomustine, and vincristine. Unfortunately, side effects are common and many patients need dose reduction, therapy postponement, or incomplete cycles of PCV due to cytotoxicity, hepatotoxicity, and cutaneous eruptions 1 . Apart from these side effects, drug hypersensitivity reactions (DHR) may occur, particularly for procarbazine.…”

“…Apart from these side effects, drug hypersensitivity reactions (DHR) may occur, particularly for procarbazine. There are no predictors for developing a DHR, but antiepileptic drugs are associated with an increased risk, possibly due to their hepatic enzyme‐inducing properties 1 . Procarbazine may cause various types of DHR 2,3 .…”